Sustained Investment Enthusiasm in Brain-Computer Interface: Meinian Health Poised for Breakthrough with Strategic Brain Health Initiatives

At the start of 2026, the brain-computer interface (BCI) sector got off to a strong start. Neuralink, under Elon Musk, announced the launch of mass production for its BCI devices, directly igniting investment enthusiasm in the A-share "human brain engineering" sector. The sector index rose by more than 12% in a single day, with multiple concept stocks experiencing significant price increases. Amid this capital frenzy, Meinian Onehealth, a leading enterprise in preventive medicine, has made deep inroads into the field of brain health through its dual-wheel drive strategy of "AI + disciplines." By leveraging technological barriers, scenario advantages, and data accumulation, it has built core competitiveness and is poised to become a focal point of market attention.

Breakthrough Advances in Brain-Computer Interface Technology Are Propelling the Field of Brain Health from “Niche Medical Applications” to “Large-Scale Adoption.” China has incorporated brain science and brain-inspired research into its major national science and technology initiatives. Cities such as Beijing, Shanghai, and Shenzhen have introduced specialized policies to comprehensively support industry development through R&D subsidies, expanded clinical access, and supply chain infrastructure. On the demand side, the urgent need for prevention and control of neurological disorders, including stroke and Alzheimer’s disease, is driving the integration of brain health screening and full-lifecycle management into the national public health framework, thereby injecting sustained momentum into the sector’s growth.

The capital market’s enthusiastic response serves as direct proof of the industry’s potential. By the morning close on January 5, 2026, the index for the brain engineering concept sector had surged to 6,245.59 points, with multiple stocks, including Sanbo Brain Hospital and Vishee Medical, hitting their daily upper limits. Capital interest in the brain health sector continues to rise. Industry analysts point out that as technological iterations reduce application costs and policy dividends continue to be released, the brain health track is poised to grow into a trillion-yuan market. Companies possessing technical barriers and the ability to implement practical applications will be the first to benefit.

As a leading enterprise in preventive medicine in China, Meinian Onehealth has not merely followed trends but has instead leveraged years of industry expertise and technological accumulation to deeply cultivate the brain health sector through a dual-drive strategy of “AI + Disciplines.” By implementing an “All in AI” strategy, the company has built a complete ecosystem encompassing “R&D – Clinical Application – Data Accumulation.” In collaboration with Jingsan Technology, Meinian Onehealth co-developed “Nao Rui Jia,” the first domestic brain health screening product targeting Alzheimer’s disease and stroke. Relying on high-precision brain magnetic resonance imaging (MRI) technology, the product enables intelligent medical assessment of over 100 brain regions. Integrated with AI assessment models, genetic testing, and biomarkers such as p-tau217, and combining deep learning algorithms with a standard brain database of the healthy Chinese population across all age groups, it can accurately identify early structural abnormalities and functional degeneration in the brain, facilitating the early detection of subtle lesions. The testing volume is expected to exceed one million in 2025, with a cumulative positive rate surpassing 12%. This product not only fills the gap in early brain health screening in China but also provides critical data support for the optimization and clinical application of brain-computer interface (BCI) algorithms. Looking ahead, Meinian Onehealth will continue to enhance and iterate the “Nao Rui Jia” product based on massive data accumulation, algorithmic model upgrades, and scenario expansion, striving to play a demonstrative and leading role in the field of preventive medicine for brain health in China and promoting the development of a distinctive path for China in the realm of brain science.

Backed by the systematic support of Meinian Onehealth’s eight core disciplines, the company focuses on intelligent ultrasound, brain science, respiratory and pulmonary health, gastrointestinal health, breast and cervical cancer screening, blood glucose/obesity/fatty liver management, anti-aging and genetic testing, and AI-assisted chief physician services, building a product matrix centered on “early screening + chronic disease management + ecosystem synergy.” As a core strategic sector, brain science is deeply integrated with other disciplines: the “Ultrasound Quality Control Large Model,” trained on hundreds of millions of imaging datasets, has deployed its AI real-time alert function for quality control in brain health examinations; the full-chain AI quality control system covering “pre-examination, during-examination, and post-examination” stages ensures screening accuracy, while the “Health Xiaomei” AI-assisted chief physician system has achieved an accuracy rate of 95%.

Industry-academia-research collaboration fuels continuous technological innovation. In December 2023, Meinian Onehealth Healthcare, in partnership with the Institute of Brain-like Intelligence Technology and Science at Fudan University and other institutions, launched the “China Million-Person Brain Check-up Project,” aiming to establish consensus on early screening for Alzheimer’s disease and build a brain health database for the Chinese population. The deep integration of universities’ scientific research capabilities with enterprises’ application scenarios has created a virtuous cycle of “research–translation–implementation.”

To further refine the brain health service chain, Meinian Onehealth has entered into a deep strategic partnership with Younao Galaxy (Galaxy Brain Science), aiming to achieve complementary advantages between "precise brain health screening" and "personalized brain function intervention." As the first enterprise globally to complete the clinical translation chain from personalized brain mapping to neuromodulation, Galaxy Brain Science has established an intervention matrix covering 18 categories of brain disorders. Leveraging Meinian’s nationwide health traffic entry points and extensive accumulation of brain imaging data, combined with Galaxy’s cutting-edge closed-loop diagnosis and treatment technologies in brain science, both parties are jointly constructing a full-cycle service system encompassing "brain risk screening – precise assessment – rehabilitation intervention." Currently, the collaboration has expanded from the clinically critical scenario of post-stroke rehabilitation to exploratory interventions for early-stage Alzheimer’s disease, with the core objective of significantly enhancing neurological functional recovery through data-driven precision therapy. To address industry bottlenecks related to insufficient clinical awareness and patient conversion, both parties are promoting deep resource integration within neurorehabilitation departments and co-building a cross-institutional diagnostic and therapeutic collaborative network. They plan to rapidly validate the feasibility and user value of the closed-loop service during the pilot phase, thereby paving a new path for the industrial implementation of brain health management. This partnership not only enriches the service offerings of Meinian Onehealth but also strengthens its competitive advantage in the "screening-intervention-rehabilitation" full-chain layout within the brain health sector.

Tianfeng Securities pointed out that companies with closed-loop capabilities in “policy + hardware + algorithms + clinical applications” will continue to benefit in the brain-computer interface field.

Leveraging its advantages in scenario coverage, data accumulation, and regulatory compliance, Meinian Onehealth is poised to maintain a leading position in the brain health sector. Driven by policy, technology, and market forces, Meinian Onehealth has adopted early screening for brain health as an entry point to bridge scientific research with public applications. This strategy not only opens up new growth curves for the company but also holds promise for advancing the Chinese brain-computer interface (BCI) industry toward greater accessibility and scalability.